deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03358017

Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer (YAPPETIZER)

Multicenter, Randomized, Phase II Study of Neoadjuvant Chemotherapy Associated or Not With Zoledronate and Atorvastatin in Triple Negative Breast Cancers - YAPPETIZER Study

Sponsor: Associazione Italiana per la Ricerca sul Cancro

Conditions Triple Negative Breast Cancer
Interventions Atorvastatin 80mg Standard neoadjuvant cht Zoledronate
Updated 12 times since 2017 Last updated: Oct 18, 2023 Started: Mar 5, 2018 Primary completion: Jun 17, 2021 Completion: Jul 25, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Triple Negative Breast Cancer and is currently completed. Associazione Italiana per la Ricerca sul Cancro leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotNot Yet Recruiting~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshotNot Yet Recruiting~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshotRecruiting~Dec 2018 – ~Dec 2019 · 12 months · monthly snapshotRecruiting~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshotRecruiting~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshotRecruiting~Mar 2022 – ~Apr 2023 · 13 months · monthly snapshotUnknown Status~Apr 2023 – ~Nov 2023 · 7 months · monthly snapshotActive Not Recruiting~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Nov 2023 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Apr 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Unknown Status → Active Not Recruiting

▶ Show 7 earlier versions

  1. Mar 2022 — Apr 2023 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  2. Jan 2021 — Mar 2022 [monthly]

    Recruiting PHASE2

  3. Dec 2019 — Jan 2021 [monthly]

    Recruiting PHASE2

  4. Dec 2018 — Dec 2019 [monthly]

    Recruiting PHASE2

  5. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  6. Jun 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE2

  7. Dec 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Associazione Italiana per la Ricerca sul Cancro
  • Mario Negri Institute for Pharmacological Research
Data source: Mario Negri Institute for Pharmacological Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations